Accession Number: | 0001104659-21-082597 |
Date: | 2021-06-15 |
Issuer: | CYCLACEL PHARMACEUTICALS, INC. (CYCC) |
Original Submission Date: |
SCHWARTZ BRIAN
C/O CYCLACEL PHARMACEUTICALS, INC.,
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS, NJ 07922
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-06-15 | A | 2,374 | a | $0.00 | 3,561 | direct | ||
COMMON STOCK | 2021-06-15 | A | 1,187 | a | $0.00 | 3,561 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 6.69 | 2021-06-15 | deemed execution date | A | 4,748 (a) | 2022-06-15 | 2031-06-15 | common stock 4,748 | $6.69 | 7,122 | direct | |
STOCK OPTION (RIGHT TO BUY) | 6.69 | 2021-06-15 | deemed execution date | A | 2,374 (a) | 2024-06-15 | 2031-06-15 | common stock 2,374 | $6.69 | 7,122 | direct |
ID | footnote |
---|---|
f1 | the reporting person received an award of 2,374 restricted stock units on june 15, 2021, which shall vest in full on june 15, 2022. |
f2 | the reporting person received an award of 1,187 restricted stock units on june 15, 2021, which shall vest in three equal installments on june 15, 2022, june 15, 2023, and june 15, 2024. |
f3 | these options were granted to dr. schwartz for his services as a member of the board of directors of cyclacel pharmaceuticals, inc. |